Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: A 12-week study with plasma levels

Journal of Psychopharmacology

Volumn 24, Issue 8, 2010, Pages 1193-1199

  Volonteri, L S ^a   Colasanti, A ^b   Cerveri, G ^a   Fiorentini, A ^c   De Gaspari, I F ^b   Mauri, M C ^b   Valli, A ^d   Papa, P ^d   Mencacci, C ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Ospedale Salvini   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

clinical response; duloxetine; major depressive disorder; plasma levels

Indexed keywords

DULOXETINE;

ADULT; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HEADACHE; HOT FLUSH; HUMAN; INCIDENCE; INSOMNIA; IRRITABILITY; LIBIDO; MAJOR DEPRESSION; MALE; MOOD; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; AGED; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955164450     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109104863     Document Type: Article

References (40)

1. American Psychiatric Association (2000) DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders, Fourth ed. Washington DC: Text Revision, APA.
2. Baumann, P., Hiemke, C., Ulrich, S., Eckermann, G., Gaertner, I., Gerlach, M., Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie ; et al. (2005) The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 7: 231-247. (Pubitemid 41284688)
3. Beck, AT, Ward, CH, Mendelson, M., Mock, J., Erbaugh, J. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571.
4. Brannan, SK, Mallinckrodt, CH, Brown, EB, Wohlreich, MM, Watkin, JG, Schatzberg, AF (2005 b) Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39: 43-53.
5. Brannan, SK, Mallinckrodt, CH, Detke, M., Watkin, JG, Tollefson, GD (2005 a) Onset of action of duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res 39: 161-172.
6. Bymaster, FP, Dreshfield-Ahmad, LJ, Threlkeld, PG, Shaw, JL, Thompson, L., Nelson, DL, et al. (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-880.
7. Chalon, S., Bieck, PR, Goldstein, DJ, Detke, MJ, Bymaster, FP, Potter, WZ, et al. (2002) The tyramine pressor test may have limited sensitivity, especially in the presence of dual serptonin/ norepinephrine uptake inhibition. Neuropsychopharmacology 26: 698-701.
8. Detke, MJ, Lu, Y., Goldstein, DJ, Hayes, JR, Demitrack, MA (2002 a) Duloxetine, 60 mg once daily, for major depressive disorder: a randomized duoble-blind placebo-controlled trial. J Clin Psychiatry 63: 308-315.
9. Detke, MJ, Lu, Y., Goldstein, DJ, McNamara, RK, Demitrack, MA (2002 b) Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36: 383-390.
10. Detke, MJ, Wiltse, CG, Mallinckrodt, CH, McNamara, RK, Demitrack, MA, Bitter, I. (2004) Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo and paroxetine-controlled trial. Eur Neuropsychopharmacol 14: 457-470.
11. Duckett, JR, Vella, M., Kavalakuntla, G., Basu, M. (2007) Tolerability and efficacy of duloxetine in a nontrial situation. BJOG 14: 543-547.
12. Dunner, DL, Goldstein, DJ, Mallinckrodt, CH, Lu, Y., Detke, MJ (2003) Duloxetine in the treatment of symptoms associated with depression. Depress Anxiety 18: 53-61.
13. Goldstein, D., Lu, Y., Detke, MJ, Wiltse, C., Mallinckrodt, C., Demitrack, MA (2004 a) Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24: 389-399.
14. Goldstein, DJ, Lu, Y., Detke, MJ, Hudson, J., Iyengar, S., Demitrack, MA (2004 b) Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 45: 17-28.
15. Goldstein, DJ, Mallinckrodt, CH, Lu, Y., Demitrack, MA (2002) Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63: 225-231.
16. Guy, W. (1976) Assessment Manual for Psychopharmacology. Rockville: National Institutes of Mental Health.
17. Hamilton, M. (1959) The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
18. Hamilton, M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
19. Hirschfeld, RM, Mallinckrodt, CH, Lee, TC, Detke, MJ (2005) Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 21: 170-177.
20. Hudson, JI, Wohlreich, MM, Kajdasz, DK, Mallinckrodt, CH, Watkin, JG, Martynov, OV (2005) Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol Clin Exp 20: 327-341.
21. Judd, LL, Paulus, MJ, Schetter, PJ, Akiskal, HS, Endicott, J., Leon, AC, et al. (2000) Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness ? Am J Psychiatry 157: 1501-1504.
22. Kuo, F., Gillespie, TA, Kulanthaivel, P., Lantz, RJ, Ma, TW, Nelson, DL, et al. (2004) Synthesis and biologic activity of some known putative duloxetine metabolites. Bioorg Med Chem Lett 14: 3481-3486.
23. Mallinckrodt, CH, Prakash, A., Andorn, AC, Watkin, JG, Wohlreich, MM (2006) Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 40: 337-348.
24. Mauri, MC, Fiorentini, A., Cerveri, G., Volonteri, LS, Regispani, F., Malvini, L., et al. (2003) Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. Hum Psychopharmacol Clin Exp 18: 385-388.
25. Mauri, MC, Laini, V., Bitetto, A., Boscati, L., Scalvini, M., Mapelli, L. (1999) Long term efficacy of paroxetine in major depression: a study with plasma levels. Int Clin Psychiatr Clin Pract 2: 115-119.
26. Mauri, MC, Laini, V., Cerveri, G., Scalvini, ME, Volonteri, LS, Regispani, F., et al. (2002) Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. Progr Neuro-Psychopharmacol Biol Psychiatry 26: 597-601.
27. Moller, HJ (2000) Rating depressed patients: observer-vs seldassessment. Eur Psychiatry 15: 160-172.
28. Nemeroff, CB, Schatzberg, AF, Goldstein, DJ, Detke, MJ, Mallinckrodt, C., Lu, Y., et al. (2002) Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36: 106-113.
29. Perahia, DG, Gilaberte, I., Wang, F., Wiltse, CG, Huckins, SA, Clemens, JW, et al. (2006) Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 188: 346-353.
30. Raskin, J., Goldstein, DJ, Mallinckrodt, CH, Ferguson, MB (2003) Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 64: 1237-1244.
31. Sharma, A., Goldberg, MJ, Cerimele, BJ (2000) Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40: 161-167.
32. Skinner, MH, Kuan, HY, Pan, A., Sathirakul, K., Knadler, MP, Gonzales, CR, et al. (2003) Duloxetine is both an inhibitor and a substrate of cytocrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 73: 170-177.
33. Stewart, DE, Wohlreich, MM, Mallinckrodt, CH, Watkin, JG, Kornstein, SG (2006) Duloxetine in the treatment of major depressive disorder: comparison of safety and tolerability in male and female patients. J Affect Disord 94: 183-189.
34. Suri, A., Reddy, S., Gonzales, C., Knadler, MP, Branch, RA, Skinner, MH (2005) Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J of Clin Pharmacol Ther 43: 78-84.
35. Takano, A., Suzuki, K., Kosaka, J., Ota, M., Nozaki, S., Ikoma, Y., et al. (2006) A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology 185: 395-399.
36. Thase, ME, Tran, PV, Wiltse, C., Pangallo, BA, Mallinckrodt, C., Detke, MJ (2005) Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 25: 132-140.
37. Wise, TN, Perahia, DG, Pangallo, BA, Losin, WG, Wiltse, CG (2006) Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. J Clin Psychiatry 8: 269-278.
38. Wohlreich, MM, Mallinckrodt, CH, Watkin, JG, Hay, DP (2004) Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr 4: 1-10.
39. Wohlreich, MM, Martinez, JM, Mallinckrodt, CH, Prakash, A., Watkin, JG, Fava, M. (2005) An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 25: 552-560.
40. Wong, DT, Bymaster, FP (2002) Dual serotonin and noradrenaline uptake inhibitor class of antidepressants - potential for greater efficacy or just hype ? Prog Drug Res 58: 169-222.